Cardiovascular risk of adipokines: a review

Journal of International Medical Research

Volumn 46, Issue 6, 2018, Pages 2082-2095

  Dutheil, Frédéric ^a,b,c,d   Gordon, Brett Ashley ^e   Naughton, Geraldine ^c   Crendal, Edward ^c   Courteix, Daniel ^c,f   Chaplais, Elodie ^c,f   Thivel, David ^f   Lac, Gérard ^f   Benson, Amanda Clare ^g  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^d WittyFit   (France)

^e LA TROBE UNIVERSITY   (Australia)

^f CLERMONT AUVERGNE UNIVERSITY   (France)

^g RMIT UNIVERSITY   (Australia)

Author keywords

adipokines; appetite; cardiovascular disease; central obesity; inflammation; Metabolic syndrome; visceral adipose tissue

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER;

APPETITE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; ENERGY BALANCE; FOOD INTAKE; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRA-ABDOMINAL FAT; LIPID STORAGE; OBESITY; REVIEW; CARDIOVASCULAR DISEASE; COMPLICATION; INFLAMMATION; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ADIPOKINES; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME; OBESITY; RISK FACTORS;

EID: 85044510294     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060517706578     Document Type: Review

References (114)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428.
2. Bjorntorp P. Classification of obese patients and complications related to the distribution of surplus fat. Am. J. Clin. Nutr 1987; 45(5 Suppl): 1120–1125.
3. Kissebah AH, Vydelingum N, Murray R, Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab 1982; 54: 254–260.
4. Nagaretani H, Nakamura T, Funahashi T, Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance. Diabetes Care 2001; 24: 2127–2133.
5. Yamashita S, Nakamura T, Shimomura I, Insulin resistance and body fat distribution. Diabetes Care 1996; 19: 287–291.
6. Fujioka S, Matsuzawa Y, Tokunaga K, Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54–59.
7. Kanai H, Matsuzawa Y, Kotani K, Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 1990; 16: 484–490.
8. Dutheil F, Lesourd B, Courteix D, Blood lipids and adipokines concentrations during a 6-month nutritional and physical activity intervention for metabolic syndrome treatment. Lipids Health Dis 2010; 9: 148–148.
9. Dutheil F, Walther G, Chapier R, Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet - the RESOLVE Trial. Lipids Health Dis 2014; 13: 112–112.
10. Nakajima T, Fujioka S, Tokunaga K, Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am. J. Cardiol 1989; 64: 369–373.
11. Nakamura T, Tokunaga K, Shimomura I, Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239–246.
12. Dutheil F, Lac G, Lesourd B, Different modalities of exercise to reduce visceral fat mass and cardiovascular risk in metabolic syndrome: the RESOLVE randomized trial. Int. J. Cardiol 2013; 168: 3634–3642.
13. Boudet G, Walther G, Courteix D, Paradoxical dissociation between heart rate and heart rate variability following different modalities of exercise in individuals with metabolic syndrome: The RESOLVE study. Eur J Prev Cardiol 2017; 24: 281–296.
14. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet 2005; 366: 1059–1062.
15. Alberti KG, Eckel RH, Grundy SM, Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120: 1640–1645.
16. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011; 18: 629–639.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med 1998; 15: 539–553.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
19. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–2556.
20. Schindler AE, Ebert A, Friedrich E. Conversion of androstenedione to estrone by human tissue. J. Clin. Endocrinol. Metab 1972; 35: 627–630.
21. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc. Nutr. Soc 2005; 64: 163–169.
22. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. North Am 2008; 37: 753–768, x–xi.
23. Hotamisligil GS, Arner P, Caro JF, Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest 1995; 95: 2409–2415.
24. Weisberg SP, McCann D, Desai M, Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest 2003; 112: 1796–1808.
25. Whitehead JP, Richards AA, Hickman IJ, Adiponectin–a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264–280.
26. Azuma K, Katsukawa F, Oguchi S, Correlation between serum resistin level and adiposity in obese individuals. Obes. Res 2003; 11: 997–1001.
27. Leinonen E, Hurt-Camejo E, Wiklund O, Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387–394.
28. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol 2004; 15: 2792–2800.
29. Alessi MC, Peiretti F, Morange P, Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860–867.
30. Fukuhara A, Matsuda M, Nishizawa M, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.
31. Zhang QX, Magovern CJ, Mack CA, Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J. Surg. Res 1997; 67: 147–154.
32. Lafontan M. Historical perspectives in fat cell biology: the fat cell as a model for the investigation of hormonal and metabolic pathways. Am J Physiol Cell Physiol 2012; 302: C327–C359.
33. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N. Y. Acad. Sci 2010; 1212: E1–E19.
34. Pacholczyk M, Ferenc T, Kowalski J. [The metabolic syndrome. Part II: its mechanisms of development and its complications]. Postepy Hig Med Dosw (Online) 2008; 62: 543–558. [in Polish, English Abstract].
35. Steppan CM, Bailey ST, Bhat S, The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312.
36. Chandran M, Phillips SA, Ciaraldi T, Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442–2450.
37. Lafontan M, Viguerie N. Role of adipokines in the control of energy metabolism: focus on adiponectin. Curr Opin Pharmacol 2006; 6: 580–585.
38. Stefan N, Stumvoll M. Adiponectin–its role in metabolism and beyond. Horm. Metab. Res 2002; 34: 469–474.
39. Trujillo ME, Scherer PE. Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med 2005; 257: 167–175.
40. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003; 3: 207–213.
41. Li S, Shin HJ, Ding EL, Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179–188.
42. Tsigos C, Kyrou I, Chala E, Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48: 1332–1335.
43. Hotamisligil GS, Murray DL, Choy LN, Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A 1994; 91: 4854–4858.
44. Uysal KT, Wiesbrock SM, Marino MW, Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610–614.
45. Ventre J, Doebber T, Wu M, Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526–1531.
46. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab 1998; 83: 847–850.
47. Bastard JP, Jardel C, Bruckert E, Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab 2000; 85: 3338–3342.
48. Klover PJ, Zimmers TA, Koniaris LG, Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784–2789.
49. Kim JH, Kim JE, Liu HY, Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J. Biol. Chem 2008; 283: 708–715.
50. Al-Dokhi LM. Adipokines and etiopathology of metabolic disorders. Saudi Med J 2009; 30: 1123–1132.
51. Ma LJ, Mao SL, Taylor KL, Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336–346.
52. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vac. Biol 2006; 26: 2200–2207.
53. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337–350.
54. Van Harmelen V, Reynisdottir S, Eriksson P, Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913–917.
55. Schwartz MW, Woods SC, Porte D, Jr. Central nervous system control of food intake. Nature 2000; 404: 661–671.
56. Legradi G, Emerson CH, Ahima RS, Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997; 138: 2569–2576.
57. Ahima RS, Prabakaran D, Mantzoros C, Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250–252.
58. Howard JK, Lord GM, Matarese G, Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest 1999; 104: 1051–1059.
59. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol. Today 2000; 21: 192–199.
60. Thundyil J, Pavlovski D, Sobey CG, Adiponectin receptor signalling in the brain. Br. J. Pharmacol 2012; 165: 313–327.
61. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem 2009; 20: 831–839.
62. Bassi M, do Carmo JM, Hall JE, Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats. Peptides 2012; 37: 1–5.
63. Shklyaev S, Aslanidi G, Tennant M, Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc. Natl. Acad. Sci. U. S. A 2003; 100: 14217–14222.
64. Wallenius V, Wallenius K, Ahren B, Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med 2002; 8: 75–79.
65. Hallschmid M, Randeva H, Tan BK, Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 2009; 58: 637–640.
66. Bottcher Y, Teupser D, Enigk B, Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab 2006; 91: 2725–2731.
67. Blakemore AI, Meyre D, Delplanque J, A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 2009; 17: 1549–1553.
68. Cline MA, Nandar W, Prall BC, Central visfatin causes orexigenic effects in chicks. Behav. Brain Res 2008; 186: 293–297.
69. Sun G, Bishop J, Khalili S, Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am. J. Clin. Nutr 2007; 85: 399–404.
70. Yang H, Yang T, Baur JA, Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095–1107.
71. Carrero JJ, Witasp A, Stenvinkel P, Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol. Dial. Transplant 2010; 25: 901–906.
72. Reilly MP, Lehrke M, Wolfe ML, Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932–939.
73. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J 1990; 265: 621–636.
74. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest 2003; 111: 1805–1812.
75. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J. Endocrinol 2013; 216: T17–36.
76. Johnson BD, Kip KE, Marroquin OC, Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation (WISE). Circulation 2004; 109: 726–732.
77. Bornstein SR, Licinio J, Tauchnitz R, Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J. Clin. Endocrinol. Metab 1998; 83: 280–283.
78. Hasty AH, Shimano H, Osuga J, Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem 2001; 276: 37402–37408.
79. Simonds SE, Pryor JT, Ravussin E, Leptin mediates the increase in blood pressure associated with obesity. Cell 2014; 159: 1404–1416.
80. Wallace AM, McMahon AD, Packard CJ, Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052–3056.
81. Verma S, Li SH, Wang CH, Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736–740.
82. Calabro P, Samudio I, Willerson JT, Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335–3340.
83. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917–2921.
84. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev 2005; 26: 439–451.
85. Hopkins TA, Ouchi N, Shibata R, Adiponectin actions in the cardiovascular system. Cardiovasc. Res 2007; 74: 11–18.
86. Ouchi N, Kihara S, Arita Y, Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–2476.
87. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042–3047.
88. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am. J. Physiol 1994; 266(6 Pt 2): H2535–H2541.
89. Walther G, Obert P, Dutheil F, Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler. Thromb. Vac. Biol 2015; 35: 1022–1029.
90. Choy JC, Granville DJ, Hunt DW, Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J. Mol. Cell. Cardiol 2001; 33: 1673–1690.
91. Hermann C, Assmus B, Urbich C, Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler. Thromb. Vac. Biol 2000; 20: 402–409.
92. Serrano-Ferrer J, Crendal E, Walther G, Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial. Metabolism 2016; 65: 1350–1360.
93. Crendal E, Walther G, Vinet A, Myocardial deformation and twist mechanics in adults with metabolic syndrome: Impact of cumulative metabolic burden. Obesity (Silver Spring) 2013; 21: E679–E686.
94. Burstein SA, Peng J, Friese P, Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996; 14(Suppl 1): 154–162.
95. Wassmann S, Stumpf M, Strehlow K, Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res 2004; 94: 534–541.
96. Vinet A, Obert P, Dutheil F, Impact of a lifestyle program on vascular insulin resistance in metabolic syndrome subjects: the RESOLVE study. J. Clin. Endocrinol. Metab 2015; 100: 442–450.
97. Ridker PM, Hennekens CH, Buring JE, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med 2000; 342: 836–843.
98. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol. Clin 2003; 21: 315–325.
99. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–462.
100. Fain JN, Madan AK, Hiler ML, Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273–2282.
101. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes. Metab. Res. Rev 2000; 16: 192–201.
102. Serrano-Ferrer J, Walther G, Crendal E, Right ventricle free wall mechanics in metabolic syndrome without type-2 diabetes: effects of a 3-month lifestyle intervention program. Cardiovasc Diabetol 2014; 13: 116–116.
103. Kiriakidis S, Andreakos E, Monaco C, VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J. Cell Sci 2003; 116(Pt 4): 665–674.
104. Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J. Anim. Sci 2004; 82: 925–934.
105. Bonnefond A, Saulnier PJ, Stathopoulou MG, What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? PLoS One 2013; 8: e55921–e55921.
106. Yang Y, Li Z, Tao HF, An elevated plasma level of visfatin increases the risk of myocardial infarction. Genet Mol Res 2014; 13: 8586–8595.
107. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin. Exp. Rheumatol 2009; 27: 222–228.
108. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol 2006; 24: 309–312.
109. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol 2006; 24: 373–379.
110. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol 2008; 26: 596–603.
111. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin. Exp. Rheumatol 2008; 26: 311–316.
112. Pina T, Genre F, Lopez-Mejias R, Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J. Eur. Acad. Dermatol. Venereol 2015; 29: 1995–2001.
113. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin. Exp. Rheumatol 2010; 28: 56–62.
114. Miranda-Filloy JA, Lopez-Mejias R, Genre F, Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-alpha antagonist therapy. Clin. Exp. Rheumatol 2013; 31: 538–545.